Where Are They Now? Checking In With Four Alzheimer’s Disease Start-Ups
This article was originally published in Start Up
Executive Summary
Four start-ups previously profiled in START-UP – CoMentis, EnVivo Pharmaceuticals, Avid Radiopharmaceuticals and AC Immune SA – show how some biotechs have successfully ridden through the rough patches any company brave enough to tackle Alzheimer’s disease will likely face.
You may also be interested in...
Alzheimer's Dx: An Essential Piece of the Puzzle
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.
Lilly To Cease Development Of Alzheimer's Drug
Eli Lilly announced August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent.
Elan's High Wire Act Finds a Semi-Safe Net
Elan's and Johnson & Johnson's multi-faceted Alzheimer's disease partnership, announced on July 2, addresses the strategic needs of both parties--but also creates new uncertainties.
Need a specific report? 1000+ reports available
Buy Reports